ABSTRACT
Purpose Six-19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions.
Methods We analysed sera of 430 COVID-19 patients with severe and critical disease from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome.
Results The prevalence of neutralizing AABs to IFN-α and IFN-ω in COVID-19 patients was 4.2% (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs were detectable exclusively in critically affected, predominantly male (83%) patients (7.6% IFN-α and 4.6% IFN-ω in 207 patients with critical COVID-19). IFN-AABs were present early post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with higher mortality (92.3% versus 19.1 % in patients without IFN-AABs). TPE reduced levels of IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients compared to those not undergoing TPE.
Conclusion IFN-AABs may serve as early biomarker for development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients according to our algorithm for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies.
Competing Interest Statement
V.M.C is named together with Euroimmun GmbH on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. Technische Universitaet Berlin, Freie Universitaet Berlin and Charite - Universitaetsmedizin have filed a patent application for siRNAs inhibiting SARS-CoV-2 replication with D.N. as co-author. J.C.S, T.S (full departmental disclosure): the department of Intensive Care Medicine has/had research and/or development/consulting contracts with (full disclosure) Orion Corporation, Abbott Nutrition International, B. Braun Medical AG, CSEM SA, Edwards Lifesciences Services GmbH/SA, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Phagenesis Ltd, Cytel, and Nestle. No personal financial gains resulted from respective development/consulting contracts and/or educational grants.
Funding Statement
This work was supported by the Innovationsfond of Labor Berlin (to H.V.B, C.M., and C.G.); by funding from the Deutsche Forschungsgemeinschaft (DFG) Collaborative Research Centre CRC900 Microbial Persistence and its Control, project number 158989968, project C8 (awarded to C.G.); by funding from the Berlin Institute of Health (BIH) (to C.G.). T.C.J. is in part funded through NIAID-NIH CEIRS contract HHSN272201400008C. Parts of the work were funded by the European Union's Horizon 2020 research and innovation program through project RECOVER (GA101003589) to C.D.; the German Ministry of Research through the projects VARIPath (01KI2021) to V.M.C., and NaFoUniMedCovid19 - COVIM, FKZ: 01KX2021 to C.D., V.M.C., L.E.S., F.K. and H.H. The Pa-COVID-19 Study is funded by BIH and the German Ministry of Research NaFoUniMedCovid19 NUM-NAPKON FKZ: 01KX2021. The COV-IMMUN study is supported by the Berlin University Alliance and the BIH Clinical Study Center (BIH-CSC). KW has received funding by the Deutsche Forschungsgemeinschaft (DFG, Research Grant No. WA 1597/6-1 and WA 1597/7-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were conducted according to the Declaration of Helsinki and Good Clinical Practice principles (ICH 1996). The Pa-COVID-19 study was approved by the ethics committee of Charite Universitaetsmedizin Berlin (EA2/066/20) and is registered in the German and WHO international clinical trials registry (DRKS00021688). The Covimmun-study was approved by the ethics committee of Charite Universitaetsmedizin Berlin (EA1/068/20). The study Evaluation der humoralen und zellulaeren Immunantwort und der thromboembolischen Komplikationen bei Infektion mit dem neuartigen Coronavirus (nCoV19) was approved by the Kantonale Ethikkommission KEK, Bern, Switzerland, Nr. 2020-00877 and is registered under the name Characterizing the Immune Response and Neuronal Damage in COVID-19 at http://clinicaltrials.gov (NCT04510012). The three studies (COVID-19 Register Freiburg; FREEZE-Covid19 cohort and Biomarker COVID-19) were approved by the ethics committee of the University of Freiburg (EK-FR 153/20; FREEZE-Biobank EK-FR 383/19; EK-FR 225/20) and are registered in the German and WHO international clinical trials registry (DRKS00021522 for Biomarker COVID-19). The Covid-Immun study was approved by the local Ethics Committee of the Medical Faculty of Heidelberg (S148/2020) and is registered in the German clinical trials registry (DRKS00021810).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵22 Collaborators listed at the end of the article
Data Availability
All data produced in the present study are available upon reasonable request to the authors